In the News

1852 News Items found
Test tubes and glass vials and beakers sit on a desk in a laboratory.
In the Lab
A new Sloan Kettering Institute program will enhance the use of chemical principles to investigate biological processes.
Picturing the Body’s Immune Response
Q&A
Cell biologist Philipp Niethammer discusses what the zebrafish can teach us about how the body heals.
Organoid cell structures fluorescing in blue, green, and purple.
In the Lab
For the first time, scientists have shown that the gene APC, which is mutated in the vast majority of colorectal cancers, might be a promising target for future therapies.
Photo of an array of high-protein foods, including meat, cheese, milk, and nuts.
Support
Learn how to eat right and stay at a healthy weight by following these tips from MSK experts on diet and nutrition.
Portrait of a live zebrafish with dark patterning around and above the eyes
In the Lab
A team of scientists is combining sophisticated chemistry and experiments in zebrafish to develop a new cancer drug that shows early potential against melanoma and metastatic breast cancer.
Douglas Warner, Robert Weinberg, Craig Thompson
Event
MSK’s Convocation and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences Commencement celebrate the achievements of young scientists.
Proximal tubule of the kidney.
In the Lab
Memorial Sloan Kettering scientists have engineered a tiny particle that could ferry drugs directly to the kidneys and prevent their uptake in other organs.
MSK investigators Joan Massagué and Anna Obenauf
In the Lab
Outsmarting Cancer’s Survival Skills
A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.
CAR T cell therapy
In the Clinic
Cell therapies that use patients’ own immune cells to attack cancer — including CAR T cell therapy, an approach developed at MSK — are a promising and rapidly growing area of research.
Pictured: Charles Sawyers
In the Clinic
Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.